In This Article:
– Highlights continued execution across Ampligen® clinical development programs
– Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024
– Will host conference call and webcast today, November 15th at 8:30 AM ET
OCALA, Fla., Nov. 15, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Wednesday, November 15, 2023, at 8:30 AM ET (details below).
“Our team continues to make significant strides in the advancement of Ampligen® through our active human clinical studies in multiple indications, including pancreatic cancer, ovarian cancer and post-COVID conditions. Our clinical and operational execution is supported by a strong cash position and we are poised for an exciting period ahead as we approach a number of value-driving milestones, particularly in our ovarian and pancreatic cancer programs. We are dedicated to driving our clinical programs forward and building momentum to generate value for our shareholders,” commented Thomas K. Equels, Chief Executive Officer of AIM.
Recent Highlights
-
Announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.
-
Engaged Azenova, LLC, a professional business development consulting firm, to support efforts to partner AIM’s pipeline programs with a particular focus on the company’s lead asset, Ampligen®, for the treatment of various malignant solid tumors.
-
Presented an overview of Ampligen’s clinical progress in oncology at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care.
-
Announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen® (rintatolimod) as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer (TNBC). The complete topline results are now available on ClinicalTrials.gov: NCT04081389.
Upcoming Expected Ampligen Milestones
Q4 2023
-
Locally advanced pancreatic cancer (AMP-270) – Open European site
-
Metastatic pancreatic cancer (DURIPANC, Collaboration with AstraZeneca) – Begin clinical trial
-
Advanced Recurrent Ovarian Cancer – Protocol-planned interim results
-
Post-COVID Conditions (AMP-518) – Final subject completes Phase 2 study
Q1 2024
-
Post-COVID Conditions (AMP-518) – Topline data from Phase 2 study expected